Resources

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise. As a new BIA member, Emerson is committed to helping manufacturers streamline production, ensure product quality, and accelerate time to market for life-saving therapies. In this blog, David introduces the company's latest white paper.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

Cancer Research Horizons launches the Cancer Impact Club, a community of business builders whose philanthropy, expertise and networks will help shape the future of cancer treatment.

Proteintech has announced a new initiative in product characterization using AI, improving the speed and precision of antibody selection for scientists.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.

Poolbeg Pharma announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg's Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.  

Dr Edward Green, CEO of Aberdeen-based biotech company NCIMB Ltd has won the Business Leadership Award at Scotland’s Life Sciences Awards.

Life science innovation company ValiRx has announced the appointment of a Director of Research and expanded the lab team of its research subsidiary, Inaphaea BioLabs.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced today that it has raised $72 million (£58 million) in a Series A financing.

Coulter Partners successfully completed a search assignment for ExpressionEdits and is pleased to announce the placement of Dr. Amrik Basran as Chief Scientific Officer (CSO).

The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.

The Wilton Centre - one of 12 Pioneer Group sites - could provide the answer after a study highlighted the shortage of commercial laboratory space in the North East of England.

Innovate UK has announced an investment over £14 million across 29 innovative projects to help make the UK’s medicines manufacturing sector more sustainable.

Arecor establishes partnership with biopharmaceutical company to develop novel formulation of peptide therapy.

RoslinCT has entered into a strategic partnership with Gamida Cell Ltd. to manufacture their FDA-Approved Cell Therapy Omisirge.®